Search

Your search keyword '"Voskuyl AE"' showing total 346 results
Start Over Author "Voskuyl AE"
346 results on '"Voskuyl AE"'

5. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease

Author

Distler, O, Highland, Kb, Gahlemann, M, Azuma, A, Fischer, A, Mayes, Md, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, Tm, Bergna, M, Casado, G, Mannucci Walter, P, Proudman, S, Stevens, W, Thakkar, V, Troy, L, Loeffler-Ragg, J, Olschewski, H, Bondue, B, Houssiau, F, Smith, V, Wuyts, W, Johnson, S, Keystone, E, Khalidi, N, Levesque, M, Maturana Rozas, R, Silva Orellana, A, Huang, C, Li, J, Jiang, Z, Liu, Y, Xiao, W, Xu, J, Zeng, X, Zheng, Y, Zou, H, Becvar, R, Madsen, H, Søndergaard, K, Kilpeläinen, M, Myllärniemi, M, Agard, C, Allanore, Y, Bourdin, A, Cottin, V, Crestani, B, Diot, E, Dominique, S, Hachulla, E, Jouneau, S, Leroy, S, Nunes, H, Prevot, G, Wallaert, B, Wemeau, L, Aringer, M, Bewig, B, Blaas, S, Distler, J, Ehrchen, J, Ewert, R, Gläser, S, Henes, J, Hunzelmann, N, König, R, Kötter, I, Kreuter, M, Prasse, A, Schulze-Koops, H, Sfikakis, P, Vlachoyiannopoulos, P, Losonczy, G, Behera, D, Gayathri Devi HJ, Kadel, J, Kawedia, M, Kumar, D, Kumar, U, Lokhande, R, Malpani, A, Mohan, M, Nalawade, A, Parakh, U, Swarnakar, R, Shobha, V, Thangakunam, B, Udwadia, Z, Henry, M, O'Reilly, K, Balbir-Gurman, A, Kramer, M, Litinsky, I, Rosner, I, Cutolo, M, Gabrielli, A, Iaccarino, L, Pesci, A, Riccieri, V, Vettori, S, Funakubo, Y, Inoue, Y, Kawakami, A, Kawaguchi, Y, Kawamura, T, Kondoh, Y, Nanki, T, Nishioka, Y, Nozawa, K, Oguragawa, T, Okamoto, M, Sano, H, Sasai, R, Sasaki, N, Suda, T, Takahashi, H, Takeuchi, T, Tanaka, S, Yamasaki, Y, Ch'Ng, Ss, Cheah, C, Kan, S, Raja Mohamed RB, Selman, M, de Vries-Bouwstra JK, van den Toorn, L, Vonken, M, Voskuyl, Ae, Hoffmann-Vold, Am, Seip, M, Dankiewicz-Fares, I, Olesiejuk, R, Pulka, G, Szepietowski, J, Alves, J, Bernardes, M, Cordeiro, A, Costa, J, Neves, S, Salvador, Mj, Alegre Sancho, J, Carreira Delgado, P, Castellví Barranco, I, Cifrián Martínez, J, Guillén Del Castillo, A, Ovalles, Jg, López-Longo, Fj, Rivera Gallego, A, Freire Dapena MC, Román Ivorra JA, Ekwall, Ah, Maurer, B, Mihai, Cm, Müller, R, Mahakkanukrauh, A, Nantiruj, K, Siripaitoon, B, Denton, Cp, Herrick, A, Madhok, R, West, A, Bascom, R, Criner, G, Csuka, Me, Dematte D'Amico, J, Ettinger, N, Gerbino, A, Gerke, A, Glassberg, M, Glazer, C, Golden, J, Gripaldo, R, Gupta, N, Hamblin, M, Highland, K, Ho, L, Huggins, Jt, Hummers, L, Jones, L, Kahaleh, M, Khanna, D, Kim, H, Lancaster, Lh, Luckhardt, T, Mayes, M, Mendoza Ballesteros, F, Mooney, J, Mohabir, P, Morrissey, B, Moua, T, Padilla, M, Patel, N, Perez, R, Roman, J, Rossman, M, Russell, T, Saketkoo, L, Shah, A, Shlobin, O, Scholand, Mb, Simmssetts, R, Spiera, R, Steen, V, Veeraraghavan, S, Weigt, S., Distler, O, Highland, Kb, Gahlemann, M, Azuma, A, Fischer, A, Mayes, Md, Raghu, G, Sauter, W, Girard, M, Alves, M, Clerisme-Beaty, E, Stowasser, S, Tetzlaff, K, Kuwana, M, Maher, Tm, SENSCIS Trial Investigators., Bergna M, Casado, G, Mannucci Walter, P, Proudman, S, Stevens, W, Thakkar, V, Troy, L, Loeffler-Ragg, J, Olschewski, H, Bondue, B, Houssiau, F, Smith, V, Wuyts, W, Johnson, S, Keystone, E, Khalidi, N, Levesque, M, Maturana Rozas, R, Silva Orellana, A, Huang, C, Li, J, Jiang, Z, Liu, Y, Xiao, W, Xu, J, Zeng, X, Zheng, Y, Zou, H, Becvar, R, Madsen, H, Søndergaard, K, Kilpeläinen, M, Myllärniemi, M, Agard, C, Allanore, Y, Bourdin, A, Cottin, V, Crestani, B, Diot, E, Dominique, S, Hachulla, E, Jouneau, S, Leroy, S, Nunes, H, Prevot, G, Wallaert, B, Wemeau, L, Aringer, M, Bewig, B, Blaas, S, Distler, J, Ehrchen, J, Ewert, R, Gläser, S, Henes, J, Hunzelmann, N, König, R, Kötter, I, Kreuter, M, Prasse, A, Schulze-Koops, H, Sfikakis, P, Vlachoyiannopoulos, P, Losonczy, G, Behera, D, Gayathri Devi, Hj, Kadel, J, Kawedia, M, Kumar, D, Kumar, U, Lokhande, R, Malpani, A, Mohan, M, Nalawade, A, Parakh, U, Swarnakar, R, Shobha, V, Thangakunam, B, Udwadia, Z, Henry, M, O'Reilly, K, Balbir-Gurman, A, Kramer, M, Litinsky, I, Rosner, I, Cutolo, M, Gabrielli, A, Iaccarino, Laura, Pesci, A, Riccieri, V, Vettori, S, Funakubo, Y, Inoue, Y, Kawakami, A, Kawaguchi, Y, Kawamura, T, Kondoh, Y, Nanki, T, Nishioka, Y, Nozawa, K, Oguragawa, T, Okamoto, M, Sano, H, Sasai, R, Sasaki, N, Suda, T, Takahashi, H, Takeuchi, T, Tanaka, S, Yamasaki, Y, Ch'Ng, S, Cheah, C, Kan, S, Raja Mohamed, Rb, Selman, M, de Vries-Bouwstra, Jk, van den Toorn, L, Vonken, M, Voskuyl, Ae, Hoffmann-Vold, Am, Seip, M, Dankiewicz-Fares, I, Olesiejuk, R, Pulka, G, Szepietowski, J, Alves, J, Bernardes, M, Cordeiro, A, Costa, J, Neves, S, Salvador, Mj, Alegre Sancho, J, Carreira Delgado, P, Castellví Barranco, I, Cifrián Martínez, J, Guillén Del Castillo, A, Ovalles, Jg, López-Longo, Fj, Rivera Gallego, A, Freire Dapena, Mc, Román Ivorra, Ja, Ekwall, Ah, Maurer, B, Mihai, Cm, Müller, R, Mahakkanukrauh, A, Nantiruj, K, Siripaitoon, B, Denton, Cp, Herrick, A, Madhok, R, West, A, Bascom, R, Criner, G, Csuka, Me, Dematte D'Amico, J, Ettinger, N, Gerbino, A, Gerke, A, Glassberg, M, Glazer, C, Golden, J, Gripaldo, R, Gupta, N, Hamblin, M, Highland, K, Ho, L, Huggins, Jt, Hummers, L, Jones, L, Kahaleh, M, Khanna, D, Kim, H, Lancaster, Lh, Luckhardt, T, Mayes, M, Mendoza Ballesteros, F, Mooney, J, Mohabir, P, Morrissey, B, Moua, T, Padilla, M, Patel, N, Perez, R, Roman, J, Rossman, M, Russell, T, Saketkoo, L, Shah, A, Shlobin, O, Scholand, Mb, Simmssetts, R, Spiera, R, Steen, V, Veeraraghavan, S, Weigt, S., National Institute for Health Research, British Lung Foundation, University of Zurich, and Distler, Oliver

Subjects
Male, Vital capacity, Indoles, Vital Capacity, Administration, Oral, 2700 General Medicine, 030204 cardiovascular system & hematology, Pulmonary function testing, law.invention, oral, Idiopathic pulmonary fibrosis, chemistry.chemical_compound, 0302 clinical medicine, Randomized controlled trial, law, SENSCIS Trial Investigators, CYCLOPHOSPHAMIDE, Clinical endpoint, scleroderma, 030212 general & internal medicine, Enzyme Inhibitors, 11 Medical and Health Sciences, lung diseases, Lung Diseases, Interstitial -- drug therapy -- etiology -- physiopathology, 10051 Rheumatology Clinic and Institute of Physical Medicine, General Medicine, respiratory system, Sciences bio-médicales et agricoles, Middle Aged, Protein-Tyrosine Kinases, MANIFESTATIONS, Disease Progression, Nintedanib, Female, TYROSINE KINASE INHIBITOR, Life Sciences & Biomedicine, CLINICAL-TRIALS, Adult, Diarrhea, medicine.medical_specialty, FIBROBLASTS, 610 Medicine & health, Placebo, administration, behavioral disciplines and activities, 03 medical and health sciences, FEV1/FVC ratio, Medicine, General & Internal, Double-Blind Method, Internal medicine, General & Internal Medicine, Enzyme Inhibitors -- adverse effects -- therapeutic use, SCORE, medicine, Humans, Indoles -- adverse effects -- therapeutic use, Scleroderma, Systemic -- complications -- drug therapy, Science & Technology, Scleroderma, Systemic, Protein-Tyrosine Kinases -- antagonists & inhibitors, business.industry, MORTALITY, interstitial, PULMONARY-FUNCTION, systemic, STANDARDIZATION, medicine.disease, EFFICACY, respiratory tract diseases, body regions, chemistry, adult, diarrhea, disease progression, double-blind method, enzyme inhibitors, female, humans, indoles, lung diseases, interstitial, male, middle aged, protein-tyrosine kinases, scleroderma, systemic, vital capacity, business, Lung Diseases, Interstitial, Diarrhea -- chemically induced
Abstract

Interstitial lung disease (ILD) is a common manifestation of systemic sclerosis and a leading cause of systemic sclerosis-related death. Nintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ILD., info:eu-repo/semantics/published

Published
2019

7. IDENTIFICATION OF FOUR NEW SHARED SUSCEPTIBILITY GENES IN SYSTEMIC SCLEROSIS AND CROHN¿S DISEASE THROUGH A CROSS-DISEASE META-GWAS

Author

González-Serna, David, Ochoa, Eguzkine, López-Isac, Elena, Julià, A, Degenhardt, Frauke, van Beelen Granlund, A, Carreira, PE, Simeon, CP, Ortego-Centeno, N., González-Gay, M. A., Vicente, Esther, Beltran, E, Alegre-Sancho, Juan-José, Spanish Scleroderma Group, Beretta, L., Santaniello, A, Lunardi, C., Hunzelmann, Nicolas, Riemekasten, G, Witte, T, Distler, J.H.W., Kreuter, A., Airó, P, Koeleman, B. P., Voskuyl, AE, de Vries-Bouwstra, Jeska, Radstake, TRDJ, Wijmenga, C, Assassi, S., Franke, Andre, Marsal, Sara, Mayes, Maureen D., Martín, J., and Márquez A

Published
2019

8. GWAS for systemic sclerosis identifies multiple risk loci and highlights fibrotic and vasculopathy pathways

Author

Lopez-Isac, E, Acosta-Herrera, M, Kerick, M, Assassi, S, Satpathy, AT, Granja, J, Mumbach, MR, Beretta, L, Simeon, CP, Carreira, P, Ortego-Centeno, N, Castellvi, I, Bossini-Castillo, L, David Carmona, F, Orozco, G, Hunzelmann, N, Distler, JHW, Franke, A, Lunardi, C, Moroncini, G, Gabrielli, A, de Vries-Bouwstra, J, Wijmenga, C, Koeleman, BPC, Nordin, A, Padyukov, L, Hoffmann-Vold, A-M, Lie, B, Rios, R, Callejas, JL, Vargas-Hitos, JA, Garcia-Portales, R, Camps, MT, Fernandez-Nebro, A, Gonzalez-Escribano, MF, Garcia-Hernandez, FJ, Castillo, MJ, Aguirre, MA, Gomez-Gracia, I, Fernandez-Gutierrez, B, Rodriguez-Rodriguez, L, Garcia de la Pena, P, Vicente, E, Andreu, JL, Fernandez de Castro, M, Lopez-Longo, FJ, Martinez, L, Fonollosa, V, Guillen, A, Espinosa, G, Tolosa, C, Pros, A, Rodriguez-Carballeira, M, Narvaez, FJ, Rubio-Rivas, M, Ortiz-Santamaria, V, Madronero, AB, Gonzalez-Gay, MA, Diaz, B, Trapiella, L, Sousa, A, Egurbide, MV, Fanlo-Mateo, P, Saez-Comet, L, Diaz, F, Hernandez, V, Beltran, E, Roman-Ivorra, JA, Grau, E, Alegre-Sancho, JJ, Freire, M, Blanco-Garcia, FJ, Oreiro, N, Witte, T, Kreuter, A, Riemekasten, G, Airo, P, Magro, C, Voskuyl, AE, Vonk, MC, Hesselstrand, R, Proudman, S, Stevens, W, Nikpour, M, Zochling, J, Sahhar, J, Roddy, J, Nash, P, Tymms, K, Rischmueller, M, Lester, S, Vyse, T, Herrick, AL, Worthington, J, Denton, CP, Allanore, Y, Brown, MA, Radstake, TRDJ, Fonseca, C, Chang, HY, Mayes, MD, Martin, J, Lopez-Isac, E, Acosta-Herrera, M, Kerick, M, Assassi, S, Satpathy, AT, Granja, J, Mumbach, MR, Beretta, L, Simeon, CP, Carreira, P, Ortego-Centeno, N, Castellvi, I, Bossini-Castillo, L, David Carmona, F, Orozco, G, Hunzelmann, N, Distler, JHW, Franke, A, Lunardi, C, Moroncini, G, Gabrielli, A, de Vries-Bouwstra, J, Wijmenga, C, Koeleman, BPC, Nordin, A, Padyukov, L, Hoffmann-Vold, A-M, Lie, B, Rios, R, Callejas, JL, Vargas-Hitos, JA, Garcia-Portales, R, Camps, MT, Fernandez-Nebro, A, Gonzalez-Escribano, MF, Garcia-Hernandez, FJ, Castillo, MJ, Aguirre, MA, Gomez-Gracia, I, Fernandez-Gutierrez, B, Rodriguez-Rodriguez, L, Garcia de la Pena, P, Vicente, E, Andreu, JL, Fernandez de Castro, M, Lopez-Longo, FJ, Martinez, L, Fonollosa, V, Guillen, A, Espinosa, G, Tolosa, C, Pros, A, Rodriguez-Carballeira, M, Narvaez, FJ, Rubio-Rivas, M, Ortiz-Santamaria, V, Madronero, AB, Gonzalez-Gay, MA, Diaz, B, Trapiella, L, Sousa, A, Egurbide, MV, Fanlo-Mateo, P, Saez-Comet, L, Diaz, F, Hernandez, V, Beltran, E, Roman-Ivorra, JA, Grau, E, Alegre-Sancho, JJ, Freire, M, Blanco-Garcia, FJ, Oreiro, N, Witte, T, Kreuter, A, Riemekasten, G, Airo, P, Magro, C, Voskuyl, AE, Vonk, MC, Hesselstrand, R, Proudman, S, Stevens, W, Nikpour, M, Zochling, J, Sahhar, J, Roddy, J, Nash, P, Tymms, K, Rischmueller, M, Lester, S, Vyse, T, Herrick, AL, Worthington, J, Denton, CP, Allanore, Y, Brown, MA, Radstake, TRDJ, Fonseca, C, Chang, HY, Mayes, MD, and Martin, J

Abstract

Systemic sclerosis (SSc) is an autoimmune disease that shows one of the highest mortality rates among rheumatic diseases. We perform a large genome-wide association study (GWAS), and meta-analysis with previous GWASs, in 26,679 individuals and identify 27 independent genome-wide associated signals, including 13 new risk loci. The novel associations nearly double the number of genome-wide hits reported for SSc thus far. We define 95% credible sets of less than 5 likely causal variants in 12 loci. Additionally, we identify specific SSc subtype-associated signals. Functional analysis of high-priority variants shows the potential function of SSc signals, with the identification of 43 robust target genes through HiChIP. Our results point towards molecular pathways potentially involved in vasculopathy and fibrosis, two main hallmarks in SSc, and highlight the spectrum of critical cell types for the disease. This work supports a better understanding of the genetic basis of SSc and provides directions for future functional experiments.

Published
2019

9. Influence of glucocorticoids and disease activity on total and high density lipoprotein cholesterol in patients with rheumatoid arthritis

Author

Boers, M, Nurmohamed, MT, Doelman, CJA, Lard, LR, Verhoeven, AC, Voskuyl, AE, Huizinga, TWJ, van de Stadt, RJ, Dijkmans, BAC, and van der Linden, Sj

Subjects
Corticosteroids -- Physiological aspects -- Measurement -- Health aspects, High density lipoproteins -- Measurement -- Health aspects -- Physiological aspects, Prednisolone -- Health aspects -- Physiological aspects -- Measurement, Adrenocortical hormones -- Physiological aspects -- Measurement -- Health aspects, Antirheumatic agents -- Health aspects -- Measurement -- Physiological aspects, Cholesterol metabolism -- Measurement -- Physiological aspects -- Health aspects, Rheumatoid arthritis -- Drug therapy, Health, Drug therapy, Physiological aspects, Measurement, Health aspects
Abstract

Background: Glucocorticoids induce hypercholesterolaemia, a cardiovascular risk factor, in patients with diseases other than rheumatoid arthritis (RA), but the data in RA are contradictory. Objective: To determine the effects of [...]

Published
2003

10. Diagnostic strategy for the assessment of rheumatoid vasculitis. (Extended Report)

Author

Voskuyl, AE, Hazes, JMW, Zwinderman, AH, Paleolog, EM, van der Meer, FJM, Daha, MR, and Breedveld, FC

Subjects
Polyneuropathies -- Physiological aspects -- Diagnosis -- Research, Vasculitis -- Diagnosis -- Research, Purpura (Pathology) -- Physiological aspects -- Diagnosis -- Research, Immunoglobulin A -- Physiological aspects -- Research, Rheumatic diseases -- Research -- Diagnosis, Health, Diagnosis, Physiological aspects, Research
Abstract

Objective: To determine the clinical features associated with histologically proven rheumatoid vasculitis (HRV) and the additional diagnostic value of serological markers in an inception cohort of 81 patients with rheumatoid [...]

Published
2003

11. Nailfold Videocapillaroscopic Features and Other Clinical Risk Factors for Digital Ulcers in Systemic Sclerosis: A Multicenter, Prospective Cohort Study

Author

Cutolo, Maurizio, Herrick, Ariane L., Distler, Oliver, Becker, Mike O., Beltran, Emma, Carpentier, Patrick, Ferri, Clodoveo, Inanç, Murat, Vlachoyiannopoulos, Panayiotis, Chadha‐Boreham, Harbajan, Cottreel, Emmanuelle, Pfister, Thomas, Rosenberg, Daniel, Torres, Juan V., Smith, Vanessa, Becker, Mike, Erlacher, L, Hirschl, M, Kiener, HP, Pilger, E, Smith, V, Blockmans, D, Wautrecht, J‐C, Becvár, R, Carpentier, P, Frances, C, Lok, C, Sparsa, A, Hachulla, E, Quere, I, Allanore, Y, Agard, C, Riemekasten, G, Hunzelmann, N, Stücker, M, Ahmadi‐Simab, K, Sunderkötter, C, Wohlrab, J, Müller‐Ladner, U, Schneider, M, Vlachoyianopoulos, P, Vassilopoulos, D, Drosos, A, Antonopoulos, A, Balbir‐Gurman, A, Langevitz, P, Rosner, I, Levy, Y, Cutolo, M, Bombardieri, S, Ferraccioli, G, Mazzuca, S, Grassi, W, Lunardi, C, Airó, P, Riccieri, V, Voskuyl, AE, Schuerwegh, A, Santos, L, Rodrigues, AC, Grilo, A, Amaral, MC, Román Ivorra, JA, Castellvi, I, Distler, O, Spertini, F, Müller, R, Inanç, M, Oksel, F, Turkcapar, N, Herrick, A, Denton, C, McHugh, N, Chattopadhyay, C, Hall, F, Buch, M, University of Zurich, and Cutolo, Maurizio

Subjects
0301 basic medicine, Male, EUSTAR DATABASE, Settore MED/16 - REUMATOLOGIA, RAYNAUDS-PHENOMENON, PREDICTION, 2745 Rheumatology, Logistic regression, Microscopic Angioscopy, Cohort Studies, 0302 clinical medicine, Risk Factors, Medicine and Health Sciences, Immunology and Allergy, Prospective Studies, Prospective cohort study, digital ulcers, systemic sclerosis, nailfold capillaroscopy, Peripheral Vascular Diseases, Digital Ulcers, 10051 Rheumatology Clinic and Institute of Physical Medicine, Area under the curve, VASCULAR-DISEASE, Middle Aged, MICROVASCULAR DAMAGE, 2723 Immunology and Allergy, digital ulcers, Rheumatology, Immunology, Female, medicine.symptom, SEVERE ORGAN INVOLVEMENT, Cohort study, Adult, PULMONARY ARTERIAL-HYPERTENSION, medicine.medical_specialty, nailfold capillaroscopy, 610 Medicine & health, CAPILLAROSCOPIC ANALYSIS, Systemic Sclerosis, Fingers, 03 medical and health sciences, Videocapillaroscopy, Digital Ulcers, Systemic Sclerosis, Scleroderma, Limited, Internal medicine, Skin Ulcer, medicine, Humans, Videocapillaroscopy, Aged, 030203 arthritis & rheumatology, 2403 Immunology, Scleroderma, Systemic, ENDOTHELIN RECEPTOR ANTAGONIST, Receiver operating characteristic, business.industry, Skin ulcer, Confidence interval, Surgery, 030104 developmental biology, ROC Curve, Observational study, EULAR SCLERODERMA TRIALS, business
Abstract

Objective To identify nailfold videocapillaroscopic features and other clinical risk factors for new digital ulcers (DUs) during a 6-month period in patients with systemic sclerosis (SSc). Methods In this multicenter, prospective, observational cohort study, the videoCAPillaroscopy (CAP) study, we evaluated 623 patients with SSc from 59 centers (14 countries). Patients were stratified into 2 groups: a DU history group and a no DU history group. At enrollment, patients underwent detailed nailfold videocapillaroscopic evaluation and assessment of demographic characteristics, DU status, and clinical and SSc characteristics. Risk factors for developing new DUs were assessed using univariable and multivariable logistic regression (MLR) analyses. Results Of the 468 patients in the DU history group (mean ± SD age 54.0 ± 13.7 years), 79.5% were female, 59.8% had limited cutaneous SSc, and 22% developed a new DU during follow-up. The strongest risk factors for new DUs identified by MLR in the DU history group included the mean number of capillaries per millimeter in the middle finger of the dominant hand, the number of DUs (categorized as 0, 1, 2, or ≥3), and the presence of critical digital ischemia. The receiver operating characteristic (ROC) of the area under the curve (AUC) of the final MLR model was 0.738 (95% confidence interval [95% CI] 0.681–0.795). Internal validation through bootstrap generated a ROC AUC of 0.633 (95% CI 0.510–0.756). Conclusion This international prospective study, which included detailed nailfold videocapillaroscopic evaluation and extensive clinical characterization of patients with SSc, identified the mean number of capillaries per millimeter in the middle finger of the dominant hand, the number of DUs at enrollment, and the presence of critical digital ischemia at enrollment as risk factors for the development of new DUs.

Published
2016

12. Suboptimal cardiovascular risk management in rheumatoid arthritis patients despite an explicit cardiovascular risk screening programme

Author

Heslinga, M, primary, Van Den Oever, IAM, additional, Jonker, DL, additional, Griep, EN, additional, Griep-Wentink, HRM, additional, Smulders, YM, additional, Lems, WF, additional, Boers, M, additional, Voskuyl, AE, additional, Peters, MJL, additional, Van Schaardenburg, D, additional, and Nurmohamed, MT, additional

Published
2019
Full Text
View/download PDF

14. Systemic sclerosis: state of the art on clinical practice guidelines

Author

Smith, V, Scire, CA, Talarico, R, Airo, P, Alexander, T, Allanore, Y, Bruni, C, Codullo, V, Dalm, V.A.S.H., De Vries-Bouwstra, J, Della Rossa, A, Distler, O, Galetti, I, Launay, D, Lepri, G, Mathian, A, Mouthon, L, Ruaro, B, Sulli, A, Tincani, A, Vandecasteele, E, Vanhaecke, A, Vanthuyne, M, van den Hoogen, F, van Vollenhoven, R, Voskuyl, AE, Zanatta, E, Bombardieri, S, Burmester, G, Eurico, FJ, Frank, C, Hachulla, E, Houssiau, F, Mueller-Ladner, U, Schneider, M, van Laar, JM, Vieira, A, Cutolo, M, Mosca, M, Matucci-Cerinic, M, Smith, V, Scire, CA, Talarico, R, Airo, P, Alexander, T, Allanore, Y, Bruni, C, Codullo, V, Dalm, V.A.S.H., De Vries-Bouwstra, J, Della Rossa, A, Distler, O, Galetti, I, Launay, D, Lepri, G, Mathian, A, Mouthon, L, Ruaro, B, Sulli, A, Tincani, A, Vandecasteele, E, Vanhaecke, A, Vanthuyne, M, van den Hoogen, F, van Vollenhoven, R, Voskuyl, AE, Zanatta, E, Bombardieri, S, Burmester, G, Eurico, FJ, Frank, C, Hachulla, E, Houssiau, F, Mueller-Ladner, U, Schneider, M, van Laar, JM, Vieira, A, Cutolo, M, Mosca, M, and Matucci-Cerinic, M

Published
2018

15. S2D:5 Exosomes target renal tubular epithelial cells transferring inflammatory epstein–barr virus-encoded small rna (eber1) in lupus nephritis patients

Author

Baglio, SR, primary, Masoumi, N, additional, Tsang-a-Sjoe, MW, additional, Eijndhoven, MA van, additional, Heutinck, KM, additional, Jordanova, ES, additional, ten Berge, RJ, additional, Grundberg, K, additional, Schiffelers, RM, additional, van den Wetering, J, additional, de Wildt, K, additional, Verkuijlen, SM, additional, Roelofs, J, additional, Bultink, IE, additional, Middeldorp, JM, additional, Voskuyl, AE, additional, and Pegtel, DM, additional

Published
2018
Full Text
View/download PDF

17. Influence of HLA polymorphism on persistent remission in rheumatoid arthritis. (Concise Report)

Author

Molenaar, ETH, Voskuyl, AE, van der Horst-Bruinsma, IE, Schreuder, GM Th, Zanelli, E, and Dijkmans, BAC

Subjects
Disease susceptibility -- Research -- Care and treatment, Rheumatoid arthritis -- Care and treatment -- Research, Health, Care and treatment, Research
Abstract

Background: Several studies have reported an association between the presence of the shared epitope (SE) and susceptibility to rheumatoid arthritis (RA). Recent studies have shown that certain HLA-DRB1 alleles in [...]

Published
2002

18. Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies

Author

López-Isac E, Martín JE, Assassi S, Simeón CP, Carreira P, Ortego-Centeno N, Freire M, Beltrán E, Narváez J, Alegre-Sancho JJ, Spanish Scleroderma Group, Fernández-Gutiérrez B, Balsa A, Ortiz AM, González-Gay MA, Beretta L, Santaniello A, Bellocchi C, Lunardi C, Moroncini G, Gabrielli A, Witte T, Hunzelmann N, Distler JH, Riekemasten G, van der Helm-van Mil AH, de Vries-Bouwstra J, Magro-Checa C, Voskuyl AE, Vonk MC, Molberg Ø, Merriman T, Hesselstrand R, Nordin A, Padyukov L, Herrick A, Eyre S, Koeleman BP, Denton CP, Fonseca C, Radstake TR, Worthington J, Mayes MD, Martín J, University of Queensland [Brisbane], Rheumatology Service, Hospital Clínico San Carlos, University Hospital La Paz, Madrid, Referral Center for Systemic Autoimmune Diseases, University of Milan, Department of Clinical and Experimental Medicine, University of Verona (UNIVR), Department of Dermatology, University of Cologne, Department of Internal Medicine 3, Institute for Clinical Immunology Erlangen-Nuremberg, Karolinska Institutet [Stockholm], University Medical Center [Utrecht], Laboratory of Translational Immunology [Utrecht, the Netherlands], Institute of Parasitology and Biomedicine (IPB - GRANADA), Spanish National Research Council (CSIC), Immunologie et Pathologie (EA 2216), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC Brest, and Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche

Subjects
[SDV.GEN]Life Sciences [q-bio]/Genetics, Scleroderma, Systemic, integumentary system, [SDV]Life Sciences [q-bio], Arthritis, Rheumatoid, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Genetic Loci, Risk Factors, Interferon Regulatory Factors, Humans, Genetic Predisposition to Disease, skin and connective tissue diseases, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Genome-Wide Association Study
Abstract

Systemic sclerosis (SSc) and rheumatoid arthritis (RA) are autoimmune diseases that have similar clinical and immunologic characteristics. To date, several shared SSc-RA genetic loci have been identified independently. The aim of the current study was to systematically search for new common SSc-RA loci through an interdisease meta-genome-wide association (meta-GWAS) strategy. The study was designed as a meta-analysis combining GWAS data sets of patients with SSc and patients with RA, using a strategy that allowed identification of loci with both same-direction and opposite-direction allelic effects. The top single-nucleotide polymorphisms were followed up in independent SSc and RA case-control cohorts. This allowed an increase in the sample size to a total of 8,830 patients with SSc, 16,870 patients with RA, and 43,393 healthy controls. This cross-disease meta-analysis of the GWAS data sets identified several loci with nominal association signals (P This study identified a novel shared locus, IRF4, for the risk of SSc and RA, and highlighted the usefulness of a cross-disease GWAS meta-analysis strategy in the identification of common risk loci.

Published
2016

20. AB0003 A mif promoter polymorphism is associated with the susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis patients

Author

Lόpez-Isac, E, primary, Bossini-Castillo, L, additional, Campillo-Davό, D, additional, Carmona, FD, additional, Simeόn, CP, additional, Carreira, P, additional, Callejas-Rubio, JL, additional, Castellví, I, additional, Fernández-Nebro, A, additional, Rodríguez-Rodríguez, L, additional, Rivas, M Rubio, additional, García, FJ Hernández, additional, Madroñero, AB, additional, Group, S Scleroderma, additional, Beretta, L, additional, Santaniello, A, additional, Lunardi, C, additional, Airό, P, additional, Hoffmann-Vold, A-M, additional, Kreuter, A, additional, Riemekasten, G, additional, Witte, T, additional, Hunzelmann, N, additional, Vonk, MC, additional, Voskuyl, AE, additional, Bouwstra, JDV, additional, Shiels, P, additional, Herrick, A, additional, Worthington, J, additional, Radstake, TRDJ, additional, and Martin, J, additional

Published
2017
Full Text
View/download PDF

22. Expert agreement on EULAR/EUSTAR recommendations for the management of systemic sclerosis

Author

Walker, Kyle M., Pope, Janet, Alkassab, F, Molitor, Ja, Shapiro, Ls, Fessler, Bj, Gran, Jt, Goldberg, A, Medsger, TA Jr, VALENTINI, Gabriele, Csuka, Me, Griffing, L, Herrick, A, Connolly, M, Vacca, A, Riemekasten, G, Wigley, Fm, Farge, D, Johnson, Sr, Matucci Cerinic, M, Czirjak, L, Toloza, Sm, Mahmud, Th, Frech, Tm, Voskuyl, Ae, Merkel, Pa, Domsic, R, Emery, P, Steen, V, Rudnicka, L, Denton, Cp, Clements, Pj, Chatterjee, S, Kahaleh, B, Hayat, S, Mouthon, L, Lafyatis, R, Lally, Ev, Krieg, T, Chung, L, Catoggio, Lj, Mayes, Md, Anderson, Me, Silver, R, Proudman, S, Seibold, Jr, Senécal, Jl, Stevens, W, Hachulla, E, Inanc, M, Wollheim, F, Distler, O, Katsumoto, Tr, Hsu, V, Collier, Dh, Furst, D, Mckown, K, Khanna, D, Volkov, S, Mathieu, A, Baron, M, Kaminska, Ea, Khalidi, Na, Hudson, M, Markland, J, Masetto, A, Docherty, P., Walker, Kyle M., Pope, Janet, Alkassab, F, Molitor, Ja, Shapiro, L, Fessler, Bj, Gran, Jt, Goldberg, A, Medsger, TA Jr, Valentini, Gabriele, Csuka, Me, Griffing, L, Herrick, A, Connolly, M, Vacca, A, Riemekasten, G, Wigley, Fm, Farge, D, Johnson, Sr, Matucci Cerinic, M, Czirjak, L, Toloza, Sm, Mahmud, Th, Frech, Tm, Voskuyl, Ae, Merkel, Pa, Domsic, R, Emery, P, Steen, V, Rudnicka, L, Denton, Cp, Clements, Pj, Chatterjee, S, Kahaleh, B, Hayat, S, Mouthon, L, Lafyatis, R, Lally, Ev, Krieg, T, Chung, L, Catoggio, Lj, Mayes, Md, Anderson, Me, Silver, R, Proudman, S, Seibold, Jr, Senécal, Jl, Stevens, W, Hachulla, E, Inanc, M, Wollheim, F, Distler, O, Katsumoto, Tr, Hsu, V, Collier, Dh, Furst, D, Mckown, K, Khanna, D, Volkov, S, Mathieu, A, Baron, M, Kaminska, Ea, Khalidi, Na, Hudson, M, Markland, J, Masetto, A, and Docherty, P.

Subjects
Canada, Scleroderma, Systemic, Hypertension, Pulmonary, Skin Disease, Immunology, Health Survey, Sulfonamide, Epoprostenol, Scleroderma, Europe, Systemic sclerosi, Methotrexate, Treatment Outcome, Rheumatology, North America, Vascular Disease, Practice Guidelines as Topic, Immunology and Allergy, Iloprost, Survey, Societies, Medical, Treatment guideline, Human
Abstract

Objective. The European League Against Rheumatism/EULAR Scleroderma Trials and Research group (EULAR/EUSTAR) has published recommendations for the management of systemic sclerosis (SSc). Members of the Scleroderma Clinical Trials Consortium and the Canadian Scleroderma Research Group were surveyed regarding their level of agreement with the recommendations. Methods. A survey containing the 14 EULAR/EUSTAR recommendations asked participants to indicate their level of agreement with each on a 10-point scale, from 0 (not at all) to 9 (completely agree). The survey was sent to 117 people, and 66 replies were received (56% response rate). Results. Exceptions to generally high agreement included the use of iloprost and bosentan for digital vasculopathy, methotrexate for skin involvement, and bosentan and epoprostenol for pulmonary arterial hypertension (PAH; all < 69% agreement, defined as ≥ 7 rating). Vasculopathy and PAH treatment had differences in agreement between North America and Europe (p < 0.006). Respondents who were EULAR/EUSTAR recommendation authors shared a similar level of agreement compared to those who were not, except for the use of proton pump inhibitors for the prevention of SSc-related gastroesophageal reflux disease, esophageal ulcers, and strictures. Conclusion. EULAR/EUSTAR recommendations were relatively well accepted among SSc experts. Overall reduced agreement may be due to the modest efficacy of some agents (such as methotrexate for the skin). Some regional disagreement is likely because of access differences. The Journal of Rheumatology Copyright © 2011. All rights reserved.

Published
2011

23. Identification of IL12RB1 as a novel systemic sclerosis susceptibility locus

Author

López Isac E1, Bossini Castillo, L, Guerra, Sg, Denton, C, Fonseca, C, Assassi, S, Zhou, X, Mayes, Md, Simeón, Cp, Ortego Centeno, N, Castellví, I, Carreira, P, Spanish Scleroderma Group, Gorlova, O, Beretta, L, Santaniello, A, Lunardi, Claudio, Hesselstrand, R, Nordin, A, Riemekasten, G, Witte, T, Hunzelmann, N, Kreuter, A, Distler, Jh, Voskuyl, Ae, de Vries Bouwstra, J, Koeleman, Bp, Herrick, A, Worthington, J, Radstake, Tr, Martin, J., Rheumatology, and CCA - Disease profiling

Subjects
Logistic Models, Scleroderma, Systemic, Gene Frequency, Case-Control Studies, loci, Receptors, Interleukin-12, IL12RB1, Humans, Genetic Predisposition to Disease, Rheumatoid Arthritis, Polymorphism, Single Nucleotide, Article
Published
2014

24. Development of a provisional core set of response measures for clinical trials of systemic sclerosis

Author

Khanna D, Lovell DJ, Giannini E, Clements PJ, Merkel PA, Seibold JR, Matucci Cerinic M, Denton CP, Mayes MD, Steen VD, Varga J, Furst DE, Baron M, Csuka ME, Berezne A, Briet SN, Brühlmann P, Buch MH, Catoggio L, Collier D, Crofford L, Czirják L, Derk CT, Distler O, Doyle MK, Farge Bancel D, Fessler B, Foeldvari I, Goldberg A, Gran JT, Grau R, Griffing WL, Hayat S, Herrick AL, Hsu V, Hummers LK, Inanç M, Johnson S, Kahaleh MB, Lafyatis RA, Lee P, Mahmud TH, Malcarne V, McHugh NJ, Martin RW, McKown K, Medsger TA Jr, Moreland L, Pope JE, Rich E, Rothfield NF, Schiopu E, Scorza R, Senécal JL, Shanahan J, Simms RW, Strand V, Silver RM, Sweiss N, van den Hoogen FH, Veale D, Voskuyl AE, Wigley F, Wollheim FA, VALENTINI, Gabriele, Khanna, D, Lovell, Dj, Giannini, E, Clements, Pj, Merkel, Pa, Seibold, Jr, Matucci Cerinic, M, Denton, Cp, Mayes, Md, Steen, Vd, Varga, J, Furst, De, Baron, M, Csuka, Me, Berezne, A, Briet, Sn, Brühlmann, P, Buch, Mh, Catoggio, L, Collier, D, Crofford, L, Czirják, L, Derk, Ct, Distler, O, Doyle, Mk, Farge Bancel, D, Fessler, B, Foeldvari, I, Goldberg, A, Gran, Jt, Grau, R, Griffing, Wl, Hayat, S, Herrick, Al, Hsu, V, Hummers, Lk, Inanç, M, Johnson, S, Kahaleh, Mb, Lafyatis, Ra, Lee, P, Mahmud, Th, Malcarne, V, Mchugh, Nj, Martin, Rw, Mckown, K, Medsger TA, Jr, Moreland, L, Pope, Je, Rich, E, Rothfield, Nf, Schiopu, E, Scorza, R, Senécal, Jl, Shanahan, J, Simms, Rw, Strand, V, Silver, Rm, Sweiss, N, Valentini, Gabriele, van den Hoogen, Fh, Veale, D, Voskuyl, Ae, Wigley, F, and Wollheim, Fa

Subjects
medicine.medical_specialty, Consensus, Delphi Technique, Visual analogue scale, Endpoint Determination, Immunology, Alternative medicine, Delphi method, General Biochemistry, Genetics and Molecular Biology, Article, Rheumatology, Epidemiology, Immunology and Allergy, Medicine, Humans, Multicenter Studies as Topic, computer.programming_language, Core set, Clinical Trials as Topic, Scleroderma, Systemic, business.industry, Outcome measures, Clinical trial, Treatment Outcome, Physical therapy, business, computer, Delphi
Abstract

Objective: To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc). Methods: The Scleroderma Clinical Trials Consortium (SCTC) conducted a structured, 3-round Delphi exercise to reach consensus on a core set of measures for clinical trials of SSc. Round 1 asked the SCTC investigators to list items in 11 pre-defined domains (skin, musculoskeletal, cardiac, pulmonary, cardio-pulmonary, gastrointestinal, renal, Raynaud phenomenon and digital ulcers, health-related quality of life and function, global health, and biomarkers) for SSc clinical trials. Round 2 asked respondents to rate the importance of the chosen items and was followed by a meeting, during which the Steering Committee discussed the feasibility, reliability, redundancy and validity of the items. Round 3 sought to obtain broader consensus on the core set measures. Members also voted on items that had data on feasibility but lacked data on reliability and validity, but may still be useful research outcome measures for future trials. Results: A total of 50 SCTC investigators participated in round 1, providing 212 unique items for the 11 domains. In all, 46 (92%) participants responded in round 2 and rated 177 items. The ratings of 177 items were reviewed by the Steering Committee and 31 items from the 11 domains were judged to be appropriate for inclusion in a 1-year multi-centre clinical trial. In total, 40 SCTC investigators completed round 3 and ranked 30 of 31 items as acceptable for inclusion in the core set. The Steering Committee also proposed 14 items for a research agenda. Conclusion: Using a Delphi exercise, we have developed a provisional core set of measures for assessment of disease activity and severity in clinical trials of SSc.

Published
2008

25. A6.12 Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases

Author

de Jong, TD, primary, Vosslamber, S, additional, Mantel, E, additional, de Ridder, S, additional, Wesseling, JG, additional, Kraan, TCTM van der Pouw, additional, Leurs, C, additional, Hegen, H, additional, Deisenhammer, F, additional, Killestein, J, additional, Lundberg, IE, additional, Vencovsky, J, additional, Nurmohamed, MT, additional, van Schaardenburg, D, additional, Bultink, IEM, additional, Voskuyl, AE, additional, Pegtel, DM, additional, van der Laken, CJ, additional, Bijlsma, JW, additional, and Verweij, CL, additional

Published
2016
Full Text
View/download PDF

30. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis

Author

van Tellingen, A, Voskuyl, AE, Vervloet, MG, Bijl, MA (Maarten), de Sevaux, RGL, Berger, Stefan, Derksen, RHWM, Berden, JHM, Virology, and Internal Medicine

Subjects
immune system diseases, skin and connective tissue diseases
Abstract

Proliferative lupus nephritis is a strong predictor of morbidity and mortality in patients with systemic lupus erythematosus. Despite improvements in the management of lupus nephritis, a significant number of the patients do not respond to immunosuppressive therapy and progress to end-stage renal failure. In order to optimise the diagnostic strategy and treatment of patients with proliferative lupus nephritis, guidelines are needed. In this review, the Dutch Working Party on Systemic Lupus Erythematosus provides recommendations regarding four important areas in patients with proliferative lupus nephritis: I) indications for a first renal biopsy, II) definitions of treatment response, III) selection of treatment options, and IV) indications for a repeat biopsy.

Published
2012

35. Receptor for advanced glycation end products (RAGE) polymorphisms are associated with systemic lupus erythematosus and disease severity in lupus nephritis

Author

Martens, HA, primary, Nienhuis, HLA, additional, Gross, S, additional, der Steege, G van, additional, Brouwer, E, additional, Berden, JHM, additional, Sévaux, RGL de, additional, Derksen, RHWM, additional, Voskuyl, AE, additional, Berger, SP, additional, Navis, GJ, additional, Nolte, IM, additional, Kallenberg, CGM, additional, and Bijl, M, additional

Published
2012
Full Text
View/download PDF

36. Work ability: a new outcome measure in rheumatoid arthritis?

Author

Raterman, HG, primary, Hoving, JL, additional, Nurmohamed, MT, additional, Herenius, MMJ, additional, Sluiter, JK, additional, Lems, WF, additional, Tak, PP, additional, Dijkmans, BAC, additional, Twisk, J, additional, Frings-Dresen, MHW, additional, and Voskuyl, AE, additional

Published
2010
Full Text
View/download PDF

44. Noninvasive imaging of macrophages in rheumatoid synovitis using the 11C-(R)-PK11195 and positron emission tomography.

Author

van der Laken CJ, Elzinga EH, Kropholler MA, Molthoff CFM, van der Heijden JW, Maruyama K, Boellaard R, Dijkmans BAC, Lammertsma AA, and Voskuyl AE

Abstract

OBJECTIVE: Noninvasive imaging by positron emission tomography (PET) of macrophages in inflamed joints of patients with rheumatoid arthritis (RA) may allow early detection of disease activity. We undertook this study to investigate whether rheumatoid synovitis can be visualized by PET using the tracer (11)C-(R)-PK11195, which binds to peripheral benzodiazepine receptors (PBRs) on macrophages. METHODS: Knee joints of 11 RA patients with active arthritis of at least 1 knee joint were imaged with (11)C-(R)-PK11195 PET. Tissue uptake of (11)C-(R)-PK11195 was quantified. PET was followed by arthroscopy of the most inflamed knee joint of each RA patient. Synovial tissue samples were subjected to immunohistochemical staining. RESULTS: (11)C-(R)-PK11195 uptake on the PET scans was significantly higher in severely inflamed joints than in joints with moderate or mild signs of inflammation. In addition, tracer uptake in contralateral uninflamed knee joints of RA patients was significantly higher than in uninflamed joints of control patients without inflammatory joint disease, suggesting the presence of subclinical disease activity. PET tracer uptake in joints correlated significantly with PBR staining in the sublining of synovial tissue. PBR staining correlated significantly with CD68 staining of macrophages. CONCLUSION: (11)C-(R)-PK11195 PET imaging allows noninvasive in vivo imaging of macrophages in rheumatoid synovitis and possibly even in subclinical synovitis. Noninvasive visualization of macrophages may be useful both for detecting early synovitis and for monitoring synovitis activity during treatment. [ABSTRACT FROM AUTHOR]

Published
2008
Full Text
View/download PDF

49. Evaluation of classical complement pathway activation in rheumatoid arthritis: measurement of C1q-C4 complexes as novel activation products.

Author

Wouters D, Voskuyl AE, Molenaar ETH, Dijkmans BAC, and Hack CE

Abstract

OBJECTIVE: Novel activation products that are stable and minimally susceptible to in vitro artefacts have recently been described in the classical complement pathway. The present study assessed circulating levels of these products, i.e., covalent complexes between the recognition molecule of the classical pathway (C1q) and activated C4, in plasma samples from patients with rheumatoid arthritis (RA) to establish the relationship between these levels and the clinical and immunologic parameters in these patients. METHODS: C1q-C4 levels were measured in plasma samples from 41 patients with active RA and 43 patients with inactive RA. These levels were related to other complement activation products and to disease activity according to the Disease Activity Score in 28 joints (DAS28), using Spearman's rank correlations. RESULTS: C1q-C4 plasma levels were significantly higher in patients with active RA as compared with patients with RA in clinical remission (median 3.3 arbitrary units [AU], range 0.4-13.4 versus 1.7 AU, range 0.2-5.5; P=0.0001), suggesting that activation of the classical complement pathway reflects disease activity. This was supported by a significant correlation between C1q-C4 levels and the DAS28 (r=0.398, P=0.0002). Levels of other complement activation products, such as activated C4 (C4b/c), were also significantly elevated in patients with active disease compared with patients with inactive disease (P=0.03), and were correlated with C1q-C4 levels (r=0.329, P=0.002). Levels of C1q-C4 complexes were higher in synovial fluid samples than in plasma samples from the 4 patients tested. CONCLUSION: Systemic complement activation via the classical pathway in patients with RA correlates with disease activity. These results indicate that C1q-C4 complexes may be used as a biomarker for RA. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

50. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis.

Author

Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, and Dijkmans B

Abstract

OBJECTIVE. Treatment of patients with infliximab, a chimeric monoclonal IgG1 antibody against tumor necrosis factor, may result in the formation of infliximab-specific IgG antibodies. This study evaluated the clinical significance of these antibodies in patients with rheumatoid arthritis (RA). METHODS: Antiinfliximab antibodies were measured using a newly developed radioimmunoassay in a cohort of 51 consecutive patients with RA treated with infliximab, with a followup of 1 year. In addition, serum infliximab levels were determined by enzyme-linked immunosorbent assay. The results were analyzed in relation to the clinical response to treatment according to the European League Against Rheumatism criteria. RESULTS: Antibodies against infliximab were detected in 22 patients (43%). Patients without detectable antiinfliximab antibodies (n = 29 [57%]) were significantly more often classified as responders (20 of 29 [69%]) compared with patients with detectable antiinfliximab antibodies (8 of 22 [36%]; P = 0.04). Three patients had an infusion-related allergic reaction, all of whom had detectable antiinfliximab antibodies. CONCLUSION: In this study, nearly half of the RA patients treated with infliximab developed antiinfliximab antibodies within the first year of treatment. This seems to be clinically relevant, since development of antiinfliximab antibodies is associated with a reduced response to treatment. [ABSTRACT FROM AUTHOR]

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results